Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth
£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model
hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured
hVIVO plc (AIM & Euronext: HVO), formerly known as Open Orphan plc, and a global leader in conducting human challenge clinical trials for infectious and respiratory disease products, has announced
SAB Biotherapeutics’ investigational therapeutic for the treatment of seasonal influenza, SAB-176, has been granted both Breakthrough Therapy and Fast Track designations by the US Food and Drug Administration (FDA).
Transformational year with record EBITDA underlining strong operational delivery
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
Positive results from influenza human challenge study conducted by hVIVO